AUSTIN, Texas —Patients on dialysis who are hyporesponsive to anemia treatment have a higher risk for hospitalizations and death, according to data presented here. “Hyporesponse (hypoR) to erythropoiesis-stimulating agents (ESAs) is associated with adverse events,” Christine Ferro, BA, and colleagues wrote in a poster presented at the National Kidney Foundation Spring Clinical